TELA Bio (TELA) Cost of Revenue (2018 - 2026)

TELA Bio has reported Cost of Revenue for 9 years, with the latest figure at $5.3 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 12.41% year-over-year to $5.3 million in Q2 2026; TTM through Jun 2026 was $25.3 million, a 4.51% increase from a year earlier, with the FY2025 full-year figure at $25.6 million, up 13.92% from the prior year.
• Cost of Revenue was $5.3 million for Q2 2026 at TELA Bio, down from $6.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.0 million in Q4 2025, with the low at $3.2 million in Q1 2022.
• Average Cost of Revenue over 5 years is $5.1 million, with a median of $5.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue surged 57.54% in 2023, then decreased 12.41% in 2026.
• Over 5 years, Cost of Revenue stood at $3.4 million in 2022, then soared by 57.54% to $5.3 million in 2023, then gained by 19.97% to $6.3 million in 2024, then gained by 10.83% to $7.0 million in 2025, then slipped by 25.16% to $5.3 million in 2026.
• The last three Cost of Revenue figures came in at $5.3 million (Q2 2026), $6.4 million (Q1 2026), and $7.0 million (Q4 2025), per Business Quant data.